BofA/Merrill Lynch Upgrades Perrigo Co. (PRGO) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Perrigo Company plc Reports Third Quarter 2016 Financial Results
November 10, 2016 1:56 AM ESTDUBLIN, Nov. 10, 2016 /PRNewswire/ --Â
Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered third quarter reported net loss of $1.3 billion and reported diluted loss per share of $8.76, driven by goodwill impairment charge of $804Â million and brand intangible assets impairment charge of $866Â million; delivered third quarter reported gross margin of 37.4%, and third quarter reported operating margin of (111.8)% Realized adjusted net income of $236Â million and adjusted diluted earnings per share of $1.65; achieved third quarter adjusted gross margin of 47.5%... MorePerrigo Company Plc to Review Strategic Alternatives for Tysabri® Royalty Stream
November 10, 2016 1:56 AM ESTDUBLIN, Nov. 10, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabri® (natalizumab).
Perrigo's CEO John T. Hendrickson stated, "We continue to make progress on and take action against our stated strategic and operational plans first outlined in April 2016. Tysabri® dramatically improves the quality of life of patients with multiple sclerosis and its... More
